亚洲综合大片69999,日韩一区二区三区aaa,亚洲av熟女国产一区二区三区视,国产亚洲一区二区三区精品久久

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73198KIF5B（E15）-RET（E12） V804L/BaF3

KIF5B（E15）-RET（E12） V804L/BaF3
名稱 KIF5B（E15）-RET（E12） V804L/BaF3
型號 CBP73198
報價
特點 KIF5B（E15）-RET（E12） [V804L]/BaF3,母細胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細內(nèi)容
CBP73198
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12) [V804L]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804L]/BaF3

CBP73198 WB.png


2. Sanger of KIF5B-RET [V804L]/BaF3

CBP73198 sanger1.png


CBP73198 sanger2.png


3. Anti-proliferation assay

CBP73198 fig.jpg

Figure 4.CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804L Cells (C1).




如果你對CBP73198KIF5B（E15）-RET（E12） V804L/BaF3感興趣，想了解更詳細的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細地址：

  • 補充說明：

  • 驗證碼：

    請輸入計算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
操大美女逼射精视频| 久久精品欧美日韩精品不卡| 在线精品亚洲观看不卡欧| 欧美日韩综合在线一区| 成人黄色精品久久app| 欧美国产中文高高靖| 2021国产一区二区岛国| 91久久高清国语自产拍| 久久久久久久久中文字幕| 国产a一级毛片午夜剧院| 亚洲免费福利视频| 久久久精品日韩一区二区三区| 操老骚逼三级黄视频| 热精品韩国毛久久久久久| 美性中文网中文字幕91| 精品一区二区久久久久无码| 国产乱色国产精品免费播放| 欧美精品日韩精品中文字幕| 国产高清免费一级a久久| 亚洲欧美日韩中文v在线| A级毛片毛片免费观看久| 老司机免费福利午夜入口| 骚逼少妇被巨根爆插| 一区二中文字幕在线看国产一区| 日韩高清毛片在线观看| 欧美精品第一区二区三区| 日韩精品高清在线| 欧美十八一区二区三区| 骚逼被操视频拳交| 日本熟人妻中文字幕在线| 久久久18禁一区二区网| 国产精品538一区二区在线| 2021最新热播国产一区二区| 欧美国产人妖另类色视频| 乱伦美女小骚货视频| 99久久久国产精品美女| 阴茎大头插少妇蜜穴视频| 性色av一区二区三区天美传媒四| 极品一区二区三区av| 捆绑调教白浆一区二区三区| 国产精品视频一区二区三区分享|